Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection

2 years ago

Cambridge, MA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced topline…

CENTOGENE Announces CEO to Take Temporary Medical Leave of Absence – Biopharmaceutical Industry Veteran Kim Stratton Appointed as Interim CEO

2 years ago

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company…

ALR Technologies Releases an Open Letter to Shareholders

2 years ago

SINGAPORE, Dec. 20, 2021 (GLOBE NEWSWIRE) -- ALR Technologies (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, today…

Two esteemed doctors join CB Therapeutics in its exploration of innovative approaches to the production of novel psychedelics and cannabinoids so researchers can address the unmet needs of patient communities

2 years ago

SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- CB Therapeutics today announces the appointments of Dr. Stephen Wright and Dr.…

Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada

2 years ago

Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada Lugano, Switzerland, and Mississauga, Ontario, 20…

Levitee Labs Announces Strategic Partnership with LiveRx Research Group to Provide Equitable Access to Hepatitis C Care throughout Alberta, Canada

2 years ago

Treatment for Hepatitis C Virus (HCV) is effective in over 95% of infected patients, yet remains disproportionately unavailable to certain…

FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program

2 years ago

Exclusive license to anti-CCR8 monoclonal antibody program further strengthens FibroGen’s preclinical development pipelineHiFiBiO to receive $35 million option exercise payment,…

Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH

2 years ago

Study remains ongoing; top-line data anticipated in Q1 2022 versus near the end of the yearNEW YORK, Dec. 20, 2021…

Zogenix Submits Type II Variation Application to the European Medicines Agency (EMA) to Expand the Use of FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome

2 years ago

EMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease…

Turning Point Therapeutics Provides Regulatory Updates

2 years ago

SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation…